publication venue for
- Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation 2021
- Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study.. S1547-5271(24)03151-5. 2024
- Stuart J. Connolly, MD, April 9, 1949–June 2, 2024. 21:1456-1457. 2024
- Is electrical cardioversion independently associated with infarcts on brain magnetic resonance imaging or clinical outcomes in patients with atrial fibrillation?. S1547-5271(24)02739-5. 2024
- Retraction notice to: PO-0437 ARTIFICIAL INTELLIGENCE FOR ANALYSIS OF MOBILE CARDIAC TELEMETRY. 21:S1547-5271(24)02835-2. 2024
- Conduction system pacing versus biventricular pacing in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials. 21:881-889. 2024
- Heart rate variability and stroke or systemic embolism in patients with atrial fibrillation. 21:1509-1516. 2024
- RETRACTED: PO-04-037 ARTIFICIAL INTELLIGENCE FOR ANALYSIS OF MOBILE CARDIAC TELEMETRY. 21:S467-S468. 2024
- PO-03-071 SHORT-TERM COLCHICINE AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION – A RANDOMIZED, PLACEBO-CONTROLLED TRIAL. 20:S456-S456. 2023
- Incremental value of the signal-averaged ECG for diagnosing arrhythmogenic cardiomyopathy. 20:224-230. 2023
- B-PO04-038 PREDICTORS OF PACEMAKER IMPLANTATION AND LONG TERM PACEMAKER DEPENDENCY FOLLOWING CARDIAC SURGERY. 18:S294-S294. 2021
- Antidiabetic drugs for preventing atrial fibrillation: A new revolution?. 18:1097-1097. 2021
- Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis. 16:502-510. 2019
- Defibrillation testing and clinical outcomes after implantable cardioverter–defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. 16:83-90. 2019
- Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. 15:524-529. 2018
- Implantable cardioverter–defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. 15:386-392. 2018
- Subclinical atrial fibrillation: The significance of progression to longer episodes. 15:384-385. 2018
- Cardiac implantable electronic device infections: From recognizing risk to prevention. 14:846-847. 2017
- Long-term right ventricular implantable cardioverter-defibrillator lead performance in arrhythmogenic right ventricular cardiomyopathy. 13:1964-1970. 2016
- To the Editor— Device enabled left atrial appendage ligation—A word of caution. 13:e293-e293. 2016
- 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 13:e50-e86. 2016
- Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. 13:504-510. 2016
- Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. 12:2148-2154. 2015
- Same-day cardiac catheter ablation is safe and cost-effective: Experience from a UK tertiary center. 12:1756-1761. 2015
- Insight into the mechanism of failure of the Riata lead under advisory. 12:574-579. 2015
- Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013. 12:e5-e29. 2015
- Defibrillator discharges in a young patient: What is the underlying arrhythmia?. 11:2202-2205. 2014
- Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. 11:2156-2162. 2014
- Procainamide infusion in the evaluation of unexplained cardiac arrest: From the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). 11:1047-1054. 2014
- Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER).. 11:1047-1054. 2014
- Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: Data from the Israeli ICD Registry. 11:814-821. 2014
- Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: Data from the Israeli ICD Registry. 11:435-441. 2014
- Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia. 11:274-281. 2014
- The Canadian experience with Durata and Riata ST Optim defibrillator leads: A report from the Canadian Heart Rhythm Society Device Committee. 10:1478-1481. 2013
- Failure rate of the Riata lead under advisory: A report from the CHRS Device Committee. 10:692-695. 2013
- Scope and nature of sudden cardiac death before age 40 in Ontario: A report from the Cardiac Death Advisory Committee of the Office of the Chief Coroner. 10:517-523. 2013
- Reply to the Editor—Shocks and Mortality versus Pacing and Mortality. 10:e9-e10. 2013
- Shocks and Mortality versus Pacing and Mortality Reply. 10:E9-E10. 2013
- Implantable cardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. 9:2068-2074. 2012
- Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. 9:1923-1929. 2012
- Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. 9:1667-1673. 2012
- Reply to the Editor—Electrogram Confirmation of Atrial High-Rate Episodes. 9:e17-e18. 2012
- Ten questions: Developmentally appropriate support for pediatric testing in young children—How you can help. 9:1519-1521. 2012
- Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. 9:1241-1246. 2012
- Nonphysiologic noise early after defibrillator implantation in Canada: Incidence and implications. 9:378-382. 2012
- Intermittent atrioventricular block: What is the mechanism?. 9:154-155. 2012
- Entrainment of supraventricular tachycardia: What is the mechanism?. 8:1809-1811. 2011
- Case of long RP tachycardia responsive to adenosine: What is the mechanism?. 8:1105-1107. 2011
- Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. 8:955-960. 2011
- A rare cause of implantable cardioverter-defibrillator failure: Short-circuiting via an unused pace/sense lead. 7:1630-1631. 2010
- Microvolt T-wave alternans and electrophysiologic testing predict distinct arrhythmia substrates: Implications for identifying patients at risk for sudden cardiac death. 7:763-768. 2010
- Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. 6:1276-1279. 2009
- Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: The Canadian Heart Rhythm Society Device Advisory Committee. 6:474-477. 2009
- Can we alternate between T-wave alternans testing methods?. 6:338-340. 2009
- Bad lead? Good lead? What should we believe?. 6:210-211. 2009
- Outcome of advisory implantable cardioverter-defibrillator replacement: One-year follow-up. 5:1675-1681. 2008
- Design and implementation of a population-based registry of implantable cardioverter defibrillators (ICDs) in Ontario. 5:1250-1256. 2008
- Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee. 5:639-642. 2008
- Complications associated with defibrillation threshold testing: The Canadian experience. 5:387-390. 2008
- The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: A substudy of the Canadian Trial of Physiological Pacing (CTOPP). 4:1024-1028. 2007
- Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. 3:1132-1139. 2006
- AB2-2. 3:S3-S3. 2006
- AB2-6. 3:S4-S5. 2006
- P4-38. 3:S230-S231. 2006
- P5-56. 3:S278-S279. 2006
- P5-63. 3:S281-S281. 2006
- Differentiating arrhythmogenic right ventricular cardiomyopathy from right ventricular outflow tract ventricular tachycardia using multilead QRS duration and axis. 3:416-423. 2006
- Cardio-dynamic and vascular behaviour during head up tilt in patients with neurally mediated syncope. 2:S306-S307. 2005
- Increasing left ventricular pacing output decreases interventricular conduction time in patients with biventricular pacing systems. 2:S83-S84. 2005
- Proarrhythmic effects of anti arrhythmic drugs after pulmonary vein isolation for atrial fibrillation. 2:S198-S198. 2005
- Purkinje fiber trigger for ventricular tachycardia: Local exit block with ablation leading to change in QRS morphology and difficulty with mapping. 2:S251-S252. 2005
- Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. 2:270-275. 2005